IFNA1 and viral infectious disease: Such targeted understanding will be instrumental in designing precision immunotherapies that can selectively enhance protective responses (e.g., early IFN induction) or mitigate pathogenic inflammation (e.g., specific inflammasome inhibition), ultimately translating into more effective strategies for managing respiratory viral diseases and improving patient outcomes.